AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

755.666

+7.7451.04%

Number of Gainers:17

Number of Losers:12

Number of Flat:16

PE:- -

High:756.356

Open:753.505

Low:749.555

Close:747.921

Volume:43.52M

Turnover:201.05M

Market Cap:114.75B

Float Cap:111.15B

Loading ...

Immuron Ltd - Plans Phase 2 Trial for Imm-529 in 2026

THOMSON REUTERS

Immuron Submits Imm-529 Ind to FDA

THOMSON REUTERS

Immuron Submits Investigational New Drug Application for Clostridioides Difficile Infection Treatment Candidate to the US FDA

MT Newswires Live

Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%

MT Newswires Live

Morgans’ top large-cap picks for October 2025

BRIEF-Invion Ltd Seeks Trading Halt Pending Capital Raising Announcement

Mesoblast Ltd : Piper Sandler Raises Target Price to $35 From $24

THOMSON REUTERS

Australia shares end lower as consumer discretionary, healthcare stocks weigh

BUZZ-ASX-listed Mesoblast jumps on key drug's quarterly sales surge

Shares of CSL Fall After Canada Unit Signs LOI With Pharmaceutical Alliance

MT Newswires Live

BRIEF-Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter

What a 40% Year Taught Us: 4 Lessons from the past 12 months (and 3 new stocks to buy)

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

THOMSON REUTERS

Mesoblast Ltd - Gross Revenue of $21.9 Mln on Ryoncil Sales for Quarter

THOMSON REUTERS

ASX Value Stock Estimates Offering Opportunities In October 2025

Simply Wall St.

BRIEF-CSL Ltd - Unit Signs LoI With Pan-Canadian Pharmaceutical Alliance For Hemgenix Reimbursement

CSL Ltd - Unit Signs Loi With Pan-Canadian Pharmaceutical Alliance for Hemgenix Reimbursement

THOMSON REUTERS

MYX price rebounds after the recent 75% crash – is the bottom in?

CSL Ltd - Partners With Varmx in a Strategic Collaboration and Option Agreement to Develop Class Investigational Coagulation Treatment

THOMSON REUTERS

Opthea Ltd: Receives a$10.8 Million R&D Tax Incentive From the Australian Taxation Office - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":755.666,"timestamp":1760072399855,"preClose":747.92145,"halted":0,"volume":43515793,"delay":0,"changeRate":0.010355,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":7.744568,"latestTime":"10-10 16:00:00 AEDT","open":753.5048,"high":756.3559,"low":749.5553,"amount":201050700,"amplitude":0.009093,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1760310000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1760050800000,1760072400000]],"turnoverRate":0.001558,"increases":13,"decrements":13,"flats":17,"marketCap":114748171758,"floatMarketCap":111152797876.5625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":756.3559,"amplitude":0.009093,"preClose":747.92145,"low":749.5553,"latestPrice":755.666,"volume":43515793,"delay":0,"open":753.5048,"prevYearClose":936.801,"prevWeekClose":749.725,"prevMonthClose":712.826,"prevQuarterClose":712.826,"fiveDayClose":749.725,"twentyDayClose":740.889,"sixtyDayClose":876.9,"secType":"PLATE","market":"AU","turnoverRate":0.001558,"marketCap":114748171758,"floatMarketCap":111152797876.5625,"timestamp":1760072399855,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":17,"down":12,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2573448719","title":"Immuron Ltd - Plans Phase 2 Trial for Imm-529 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573448719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573448719?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:00","pubTimestamp":1759917600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA3Y2GPG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2573443849","title":"Immuron Submits Imm-529 Ind to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2573443849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573443849?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:00","pubTimestamp":1759917600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA3Y2GPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2573912270","title":"Immuron Submits Investigational New Drug Application for Clostridioides Difficile Infection Treatment Candidate to the US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2573912270","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573912270?lang=en_us&edition=fundamental","pubTime":"2025-10-08 14:02","pubTimestamp":1759903360,"startTime":"0","endTime":"0","summary":"Immuron  submitted an investigational new drug application to the US Food and Drug Administration  for the clinical development of IMM-529 to treat Clostridioides difficile infection and prevent recurrent infection, according to a Wednesday Australian bourse filing.It plans to initiate a second-phase clinical trial for the treatment candidate in individuals with Clostridioides difficile infection during the first half of 2026. The clinical trial is expected to enroll both first-episode and recurrent infection patients.The firm's shares rose over 1% in recent trading on Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2573151719","title":"Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573151719","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573151719?lang=en_us&edition=fundamental","pubTime":"2025-10-08 10:48","pubTimestamp":1759891712,"startTime":"0","endTime":"0","summary":"Dimerix  said the results of an analysis by Parasol are consistent with the analysis conducted last year that supported the use of proteinuria as a clinical trial endpoint for focal segmental glomerulosclerosis, a kidney disease, according to a Wednesday filing with the Australian bourse.The company said the results cannot be disclosed as they are subject to commercial-in-confidence restrictions.The company, along with its US partner Amicus Therapeutics, intends to seek feedback from the US Food and Drug Administration on the new findings in the coming months, the filing said.Shares of the company rose 7% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","DXB.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2573992055","title":"Morgans’ top large-cap picks for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573992055","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573992055?lang=en_us&edition=fundamental","pubTime":"2025-10-08 08:46","pubTimestamp":1759884366,"startTime":"0","endTime":"0","summary":"Our best ideas are those that we believe offer the highest risk-adjusted returns over a 12-month timeframe supported by a higher-than-average level of confidence. They are our most preferred sector exposures.edge with extraordinary volatility in well-held large caps . Despite. the volatile moves, expectations of a sharper slowdown failed to materialise. and solid updates from the banks and consumer sectors point to a generally. concentration and ongoing macroeconomic uncertainty mean we’re likely to. see significant divergence in stock performance. Investors should stay nimble. This month we add Dalrymple Bay Infrastructure, PWH Holdings and ARB Corp. to our Best Ideas list. We remove Amotiv.Although a softer 2H Behring result and awkward restructuring timing may unsettle investors, we see the growth engine intact, with cost savings reinforcing the path to sustained double-digit earnings growth.While execution of synergy targets will be the key, AMC has a strong track record in. GMG is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/morgans-top-large-cap-picks-for-october-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/morgans-top-large-cap-picks-for-october-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7142","BK4585","BK7016","AOV.AU","BK4533","BK7007","WDS.AU","RMD.AU","PWH.AU","BK7501","BK7099","BK4504","TGT","CSL.AU","ARB.AU","BK4532","LU1244550577.SGD","LU1244550494.USD","LU0211328371.USD","TWE.AU","BK4114","WTC.AU","BK4155","BK7510","LU0823411888.USD","BK7505","LU0052756011.USD","LU2237443382.USD","LU0128525689.USD","BK7508","AMC.AU","BK7067","BK7051","BK7155","LU2237443549.SGD","BK4597","GMG.AU","BK7506","LU2237443622.USD","BK7097","LU0310800965.SGD","BK7063","DBI.AU","BK7079","BK7503","LU1244550221.USD","BK7511","NST.AU","LU1267930227.SGD","BK4596"],"gpt_icon":0},{"id":"2573991287","title":"BRIEF-Invion Ltd Seeks Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573991287","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573991287?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:36","pubTimestamp":1759876593,"startTime":"0","endTime":"0","summary":"BRIEF-Invion Ltd Seeks Trading Halt Pending Capital Raising AnnouncementOct 8 (Reuters) - Invion Ltd IVX.AX:SEEKS TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: IVX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","IVX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2573968543","title":"Mesoblast Ltd : Piper Sandler Raises Target Price to $35 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2573968543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573968543?lang=en_us&edition=fundamental","pubTime":"2025-10-07 21:12","pubTimestamp":1759842746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MSB.AU","BK7508","BK7067","MESO","BK7501"],"gpt_icon":0},{"id":"2573343929","title":"Australia shares end lower as consumer discretionary, healthcare stocks weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2573343929","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573343929?lang=en_us&edition=fundamental","pubTime":"2025-10-07 13:43","pubTimestamp":1759815816,"startTime":"0","endTime":"0","summary":"Australia shares end lower as consumer discretionary, healthcare stocks weighASX200 inches down, 100 points below record highWesfarmers hits 1-month lowFortescue logs worst day in a weekNZ50 at 4-year peakUpdates to market closeBy Nikita Maria Jino","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nL6N3VO085:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7001","LU0266512127.USD","BK7095","LU0345777659.USD","WES.AU","BK7041","LU0788109121.HKD","LU0630314457.HKD","LU0345780950.USD","LU1078025761.USD","LU1130305938.SGD","LU0456854461.SGD","BK7153","BK7508","IE00BQJZX424.USD","LU1430597077.USD","JBH.AU","LU0266512473.USD","FMG.AU","RIO.UK","IE00BWDBJ516.SGD","LU0898667661.SGD","SG9999001143.SGD","LU0505663152.USD","BK7507","LU0612318385.USD","SG9999002521.SGD","LU1064927863.SGD","LU1023059493.AUD","LU0612318971.USD","BK5111","LU0955669360.SGD","CSL.AU","LU0345781412.USD","LU0330918003.SGD","BK7511","BK7501","LU0075056555.USD","LU0345777147.USD","BHP.AU","LU0171293334.USD","BK7129","LU0831103253.SGD","BK7067","LU0011963245.USD","IE0034235071.USD","IE00B3M56506.USD","LU0654597011.USD"],"gpt_icon":0},{"id":"2573070938","title":"BUZZ-ASX-listed Mesoblast jumps on key drug's quarterly sales surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2573070938","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573070938?lang=en_us&edition=fundamental","pubTime":"2025-10-07 10:09","pubTimestamp":1759802984,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Mesoblast jumps on key drug's quarterly sales surge** ASX-listed Mesoblast MSB.AX pares early surge to trade 8.1% higher at A$2.8 by midday in Sydney, still among the top ASX200 .AXJO ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nL6N3VO03H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2573387639","title":"Shares of CSL Fall After Canada Unit Signs LOI With Pharmaceutical Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2573387639","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573387639?lang=en_us&edition=fundamental","pubTime":"2025-10-07 10:00","pubTimestamp":1759802440,"startTime":"0","endTime":"0","summary":"Shares of CSL  fell 1% in recent Tuesday trade after the company said in a late Monday statement that its unit, CSL Behring Canada, signed a Letter of Intent  with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Hemgenix, the unit's gene therapy to treat adults with the life-threatening rare disease Hemophilia B.Under the LOI, provinces and territories outside of Quebec will list Hemgenix as part of their formularies, the statement said.CSL Behring is in talks with the province of Quebec to secure public reimbursement for Hemgenix, the statement added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169590202.USD","LU0728928796.USD","SGXZ23171101.USD","LU1169589451.USD","BK7511","BK4086","SG9999004303.SGD","CSL.AU","BK7501","BK7067","CSL","BK7508"],"gpt_icon":0},{"id":"2573388489","title":"BRIEF-Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2573388489","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573388489?lang=en_us&edition=fundamental","pubTime":"2025-10-07 09:36","pubTimestamp":1759800984,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For QuarterOct 7 (Reuters) - Mesoblast Ltd MSB.AX:GROSS REVENUE OF $21.9 MILLION ON RYONCIL SALES FOR QUARTERFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VN1UA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2573873639","title":"What a 40% Year Taught Us: 4 Lessons from the past 12 months (and 3 new stocks to buy)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573873639","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573873639?lang=en_us&edition=fundamental","pubTime":"2025-10-07 09:12","pubTimestamp":1759799547,"startTime":"0","endTime":"0","summary":"This time last year, my co-PM Ben Richardsand I wrote this piece on Livewire, reflecting on the lessons learned in the first 12 months of running the Seneca Australian Small Companies Fund. The feedback was  positive, so we’ve decided to run it back with another candid review, this time of year 2.The 12 months to 30 September were exceptional.Our fund returned 39.16% after fees for the 12 months to 30 September 2025, outperforming the S&P/ASX Small Ordinaries Index by +17.66% — placing us among the top handful of Australian equity fund managers.Our fee structure remains straightforward and aligned: 0.00% management fee, with a 20% performance fee above the RBA Cash Rate, subject to a high watermark.With that in mind, what follows are four lessons from the past 12 months, each illustrated by a real case study from our portfolio. For every lesson learned, we’ll also share a new investment idea where we’re putting those insights into action for the year ahead.: 28% premium to last close (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/what-a-40-year-taught-us-4-lessons-from-the-past-12-months-and-3-new-stocks-to-buy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/what-a-40-year-taught-us-4-lessons-from-the-past-12-months-and-3-new-stocks-to-buy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0868494708.USD","EZL.AU","BOT.AU","BK4520","RUL.AU","EHL.AU","RHI.AU","LU1917777945.USD","BK7062","BK4613","BK7100","XKO.AU","BK4597","BK4532","EOL.AU","LU2106854487.HKD","LU1974910355.USD","XJO.AU","CAT","QOR.AU","CAT.AU","GQG.AU","PNI.AU","D2O.AU","PBH.AU","XRF.AU","BK7095","LU1988902786.USD","BK4149","MIN.AU","BK4585","BK7507","XAO.AU","BK7508","ERD.AU","IFM.AU","BK7129","BK7096","RPL.AU","BK4588","BK7024","IE00BSNM7G36.USD","LU0942090050.USD","BK7088","LU2264538146.SGD","BK7031","BK7504","BK4516","IOT","LU2023250504.SGD"],"gpt_icon":0},{"id":"2573126984","title":"Ryoncil® Revenues Increase 66% in Second Quarter Post Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2573126984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573126984?lang=en_us&edition=fundamental","pubTime":"2025-10-07 07:24","pubTimestamp":1759793094,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA5JPG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7508","BK7501"],"gpt_icon":0},{"id":"2573981198","title":"Mesoblast Ltd -  Gross Revenue of $21.9 Mln on Ryoncil Sales for Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2573981198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573981198?lang=en_us&edition=fundamental","pubTime":"2025-10-07 06:45","pubTimestamp":1759790733,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1UA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7508","BK7501"],"gpt_icon":0},{"id":"2573985037","title":"ASX Value Stock Estimates Offering Opportunities In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573985037","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573985037?lang=en_us&edition=fundamental","pubTime":"2025-10-07 03:04","pubTimestamp":1759777474,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a slight pullback following a recent surge, investors are keenly observing how global factors like U.S. government actions and fluctuating commodity prices impact local indices. In this context, identifying undervalued stocks becomes crucial as they offer potential opportunities for growth amidst the current market volatility.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9021000-choice2-main-header/1585186684476","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9021000-choice2-main-header/1585186684476"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/telecom/asx-slc/superloop-shares/news/asx-value-stock-estimates-offering-opportunities-in-october","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/telecom/asx-slc/superloop-shares/news/asx-value-stock-estimates-offering-opportunities-in-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","CCR.AU","SLC.AU","BK7160","BK7007","RMC.AU","BK7505","XJO.AU","BK7501","BK7508","BK7002","BK7067","BK7051","BK7055","BK7016","ELD.AU","ART.AU","CSX.AU","NWH.AU","BK7070","CYP.AU","PWH.AU","RKN.AU","BK7123","WEB.AU","BK7117","BK7015"],"gpt_icon":0},{"id":"2573133672","title":"BRIEF-CSL Ltd - Unit Signs LoI With Pan-Canadian Pharmaceutical Alliance For Hemgenix Reimbursement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573133672","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573133672?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:26","pubTimestamp":1759753569,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Ltd - Unit Signs LoI With Pan-Canadian Pharmaceutical Alliance For Hemgenix ReimbursementOct 6 (Reuters) - CSL Ltd CSL.AX:CSL LTD - UNIT SIGNS LOI WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1NV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","CSL.AU","BK7511"],"gpt_icon":0},{"id":"2573119674","title":"CSL Ltd - Unit Signs Loi With Pan-Canadian Pharmaceutical Alliance for Hemgenix Reimbursement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573119674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573119674?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:01","pubTimestamp":1759752101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1NV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7508","BK7511","BK7067"],"gpt_icon":0},{"id":"2573559674","title":"MYX price rebounds after the recent 75% crash – is the bottom in?","url":"https://stock-news.laohu8.com/highlight/detail?id=2573559674","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573559674?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:52","pubTimestamp":1759751577,"startTime":"0","endTime":"0","summary":"MYX price is showing early signs of a technical rebound after plummeting nearly 75% from its recent high.MYX price found temporary support around $4.40, with RSI rebounding from oversold levels and slightly rising volume suggesting possible accumulation.Major resistance lies at $8.5–$9.5; a break above could target $12–$14, while falling below $5 risks new lows.MYX price crash may have been triggered by distrust after reports of sybil wallets receiving ~1% of supply during the airdrop.After recently crashing nearly 75% from the recent high of $17.5, MYX Finance  is showing the first signs of a potential short-term rebound. The steep decline broke through multiple support zones, but MYX price has now found temporary footing around the $4.40 level — a critical area where buyers started to step back in.The RSI, which had dipped deep into oversold territory, is beginning to turn upward, suggesting fading bearish momentum and the possibility of a technical bounce. Volume has also started to","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/myx-price-rebounds-after-the-recent-75-crash-is-the-bottom-in/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/myx-price-rebounds-after-the-recent-75-crash-is-the-bottom-in/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2573455679","title":"CSL Ltd - Partners With Varmx in a Strategic Collaboration and Option Agreement to Develop Class Investigational Coagulation Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2573455679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573455679?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:06","pubTimestamp":1759748810,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"gpt_icon":0},{"id":"2573675228","title":"Opthea Ltd: Receives a$10.8 Million R&D Tax Incentive From the Australian Taxation Office - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2573675228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573675228?lang=en_us&edition=fundamental","pubTime":"2025-10-06 18:15","pubTimestamp":1759745725,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":110,"code":"91000000","status":"200"}]}}